NIH tetramer core facility

This award notice was originally posted on FBO.gov on 9/11/2018.  The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. The NIAID, Division of Allergy, Immunology and Transplantation, has a requirement for continuing the NIH Tetramer Core Facility contract. The scope of activities to be conducted by the NIH Tetramer Core Facility Contractor include synthesis and distribution of soluble MHC-peptide tetramer and related reagents to the global research community, and performance of research and development to improve tetramer technologies and increase the types of products available to the biomedical research community. Such reagents include, but are not limited to, mouse, non-human primate, human, and other mammalian MHC class I monomers and tetramers; custom and pre-made mouse, non-human primate, human, and other mammalian class II tetramers; non-classical MHC TL, Qa-1, MR1, and mammalian CD1 monomers and tetramers; CD1d and other MHC ligands; and fluorophores for tetramer labeling/detection.

PLEASE NOTE:

This is an award notice for an IDIQ contract.  The Guaranteed Minimum is $50,000 and the Guaranteed Maximum is $50,000,000.  The award details section shows the Guranteed Maximum value.

Awarded contract 75N93020D00005 to EMORY UNIVERSITY for 50000000.00 on 2020-03-12.